Company Name: LBT Innovations
Announcement Date: 10/10/2016
Announcement Category: Product launch/update
Announcement Content:
• FDA clears APAS® imaging and software technology asa Class II medical device
ADELAIDE, Australia, 10 October 2016: Clever Culture Systems AG (CCS), the Swiss based joint venture between Australian medical technology company LBT Innovations Limited (ASX: LBT) and Hettich AG (Switzerland) has received clearance of its 510(k) de novosubmission to the US Food and Drug Administration (FDA) for APAS® as a Class II medical device.
APAS® (Automated Plate Assessment System) is a breakthrough artificial intelligence technology for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation. APAS® enables the faster diagnosis and reporting of infectious diseases.
Developed by LBT Innovations, APAS® has been licensed on a global, exclusive basis to CCS, which is integrating APAS with laboratory robotic instrumentation. CCS is targeting to bring APAS to market in 2017 as an automated stand-alone plate reader (APAS® Independence) followed by the integrated incubator (APAS® Incubot).
The 510(k) de novo submission used a manual version of APAS to test 10,000 patients in a series of clinical trials conducted in Australia and the US over a 12-month period. In each trial, APAS achieved its target primary endpoints and the results matched or exceeded the findings of a panel of experienced microbiologists.
Mr Brent Barnes, CEO of LBT Innovations, said, “FDA clearance follows rigorous interrogation and validation of the capabilities of APAS. The successful clinical trial program completed in 2015 and clearance by FDA also validate the underlying technology that is the core platform of our Company’s vision to integrate imaging with interpretative intelligence to deliver faster and more secure diagnoses for patients. FDA clearance is a fitting tribute tothe many years of painstaking work by LBT’s staff and partners, who together have made our shared vision a reality.”
Mrs Lusia Guthrie (recently retired LBT CEO and Chairman of CCS), confirmed that CCS is in continuing discussions with significant global diagnostics companies for the licensing of the APAS product portfolio, including APAS Independence and APAS Incubot, plus flow-on product opportunities on the drawing board all aimed at the clinical microbiology laboratory.
–ENDS—
About LBT Innovations
LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and APAS®. Based on LBT’s innovative intelligent image interpretative platform, APAS® specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich AG Switzerland to drive the commercialisation of APAS® products. LBT also has a third product in early development, WoundVue®, a proposed automated solution to assist in the management of chronic wounds.
For more information, see www.lbtinnovations.com
CONTACTS
LBT Innovations Media Relations
Brent Barnes CEO & MD
Tel: +61 (0)8 8227 1555 or Mobile 0409 677 654
E: [email protected]
Rudi Michelson – Monsoon Communications
Tel: +61 (0)3 9620 3333 or Mobile 0411 402 737
E: [email protected]
Announcement URL: http://www.lbtinnovations.com/assets/Uploads/2016-10-28Oct29-LBT-FDA-Approval-V5.pdf
About LBT Innovations:
Over the past decade, LBT Innovations has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories.
Go to Company Profile for: LBT Innovations
Announcement Contact: [email protected]
